IDYA Utang jangka cendhak perusahaan IDEAYA Corp

IDEAYA Biosciences' status as a leader in synthetic lethality is confirmed by historical short-term debt data, where the 0.00 mark serves as a current indicator. High R&D and patent protection costs create significant barriers to entry. Meanwhile, a stable capital reserve mitigates risks associated with the timelines of clinical trials for oncology drugs.

IDYA Utang jangka cendhak ideayabio.com (04.07.2022 - 29.10.2026)

Rincian analitis lan laporan data perusahaan IDEAYA Corp (IDYA)

- kuotasi saiki lan rata-rata prakiraan nilai:

Bagan rega IDEAYA Biosciences, Inc.|IDYA - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Nilai pasar IDEAYA Biosciences, Inc.|IDYA - Nilai Total Perusahaan

- data nilai buku modal saham:

Aset Bersih saben Siji Saham IDEAYA Biosciences|IDYA - Ekuitas Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku ideayabio.com|IDYA - Aset Neraca Perusahaan

- indikator total utang lan likuiditas perusahaan:

Rasio Total Utang marang Ekuitas IDEAYA Biosciences|IDYA - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas IDEAYA Biosciences|IDYA - Kewajiban utang agregat|Utang marang nilai buku IDEAYA Biosciences, Inc.|IDYA - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan IDEAYA Biosciences|Likuiditas cepet ideayabio.com

- data bathi lan kelipatan valuasi:

IDYA - Bathi pungkasan

Analisis umum perusahaan:IDEAYA Biosciences, Inc. - IDYA

To protect capital from volatility, it is essential for investors to manage liquidity by assessing the total amount of liabilities maturing within one year. The integration of robotic screening in IDEAYA Biosciences (IDYA) laboratories optimizes molecule discovery costs, while the dynamics of short-term credit obligations allow these technological expenses to be weighed against current solvency, eliminating the risk of a cash crunch within the portfolio.

Karo sapa IDEAYA Biosciences saingan